hospital admission is required at the time of possible recruitment; positive pcr or rapid antigen test for sars-cov-2 in the last 2 months other than a test at recruitment or in the 7 days prior to recruitment; participating in any other interventional drug clinical study before enrolment in the study; breastfeeding; known severe neurological disorder, especially seizures in the last 12 months; known allergy to camostat or molnupiravir; previous adverse reaction to, or currently taking, camostat or molnupiravir; patients in palliative care; pregnant women or women of childbearing potential who may become pregnant during the trial and don't agree to use any of the effective contraceptive measures lised above; judgement of the recruiting clinician deems participant ineligible.

hospital admission is required at the time of possible recruitment; positive pcr or rapid antigen test for sars-cov-2 in the last 2 months other than a test at recruitment or in the 7 days prior to recruitment; participating in any other interventional drug clinical study before enrolment in the study; breastfeeding; known severe neurological disorder, especially seizures in the last 12 months; known allergy to camostat or molnupiravir; previous adverse reaction to, or currently taking, camostat or molnupiravir; patients in palliative care; pregnant women or women of childbearing potential who may become pregnant during the trial and don't agree to use any of the effective contraceptive measures lised above; judgement of the recruiting clinician deems participant ineligible.

- hospital admission is required at the time of possible recruitment; - positive pcr or rapid antigen test for sars-cov-2 in the last 2 months other than a test at recruitment or in the 7 days prior to recruitment; - participating in any other interventional drug clinical study before enrolment in the study; - known severe neurological disorder, especially seizures in the last 12 months; - known allergy to camostat; - previous adverse reaction to, or currently taking, camostat; - patients in palliative care; - pregnant women or women of childbearing potential who may become pregnant during the trial and don't agree to use any of the effective contraceptive measures lised above; - judgement of the recruiting clinician deems participant ineligible.

- hospital admission is required at the time of possible recruitment; - positive pcr or rapid antigen test for sars-cov-2 in the last 2 months other than a test at recruitment or in the 7 days prior to recruitment; - participating in any other interventional drug clinical study before enrolment in the study; - known severe neurological disorder, especially seizures in the last 12 months; - known allergy to camostat; - previous adverse reaction to, or currently taking, camostat; - patients in palliative care; - pregnant women or women of childbearing potential who may become pregnant during the trial and don't agree to use any of the effective contraceptive measures lised above; - judgement of the recruiting clinician deems participant ineligible.

- hospital admission is required at the time of possible recruitment; - positive pcr or rapid antigen test for sars-cov-2 in the last 2 months other than a test at recruitment; - participating in any other interventional drug clinical study before enrolment in the study; - known severe neurological disorder, especially seizures in the last 12 months; - known allergy to camostat; - previous adverse reaction to, or currently taking, camostat; - patients in palliative care; - pregnant women or women of childbearing potential who may become pregnant during the trial and don't agree to use any of the effective contraceptive measures lised above; - judgement of the recruiting clinician deems participant ineligible.

- hospital admission is required at the time of possible recruitment; - positive pcr or rapid antigen test for sars-cov-2 in the last 2 months other than a test at recruitment; - participating in any other interventional drug clinical study before enrolment in the study; - known severe neurological disorder, especially seizures in the last 12 months; - known allergy to camostat; - previous adverse reaction to, or currently taking, camostat; - patients in palliative care; - pregnant women or women of childbearing potential who may become pregnant during the trial and don't agree to use any of the effective contraceptive measures lised above; - judgement of the recruiting clinician deems participant ineligible.